Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 8.01 (Other Events). Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval
- 15 demand letters and two shareholder lawsuits allege material omissions, creating litigation, delay and transaction-cost risks
- Supplemental Centerview analysis values Standard BioTools liquidation at approximately $468 million, or $1.14 per share
- Centerview’s Treeline DCF implies $3,040 million to $4,205 million equity value, or $15.88 to $21.89 per share
- UBS’ Treeline DCF implies $2,638 million to $3,313 million equity value, or $13.59 to $17.07 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.